Stock AXSM AXSOME THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Axsome Therapeutics, Inc.

Equities

AXSM

US05464T1043

Market Closed - Nasdaq
Other stock markets
 21:30:01 03/05/2024 BST 		5-day change 1st Jan Change
74.8 USD +0.82% Intraday chart for Axsome Therapeutics, Inc. +4.31% -6.02%
04-30 North American Morning Briefing : More Earnings -2- DJ
04-29 Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Axsome Therapeutics Recognizes May as Mental Health Awareness Month
GL
North American Morning Briefing : More Earnings -2-
DJ
Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says
MT
Morgan Stanley Upgrades Axsome Therapeutics to Overweight From Equalweight, Raises Price Target to $115 From $90
MT
Axsome Therapeutics highlights innovative neuroscience portfolio at the american academy of neurology 2024 annual meeting
AQ
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
GL
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
AQ
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
GL
Axsome Therapeutics Insider Sold Shares Worth $1,904,942, According to a Recent SEC Filing
MT
Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
GL
Axsome Therapeutics, Inc. Initiates Engage Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
CI
Mizuho Securities Ups Price Target on Axsome Therapeutics to $109 From $108, Keeps Buy Rating
MT
HC Wainwright Adjusts Axsome Therapeutics' Price Target to $190 From $180, Keeps Buy Rating
MT
Citigroup Adjusts Price Target on Axsome Therapeutics to $127 From $125, Maintains Buy Rating
MT
RBC Lifts Price Target on Axsome Therapeutics to $128 From $123, Says AXS-12 Reaching Primary Endpoint 'Should Enable Approval,' Keeps Outperform Rating
MT
Axsome Therapeutics Says Survey Shows Narcolepsy Symptoms Persist Despite Treatment
MT
Axsome Therapeutics : AXS-12 SYMPHONY Results - Slides
PU
Transcript : Axsome Therapeutics, Inc. - Special Call
Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
GL
Axsome Therapeutics, Inc. Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXSM Stock
  4. News Axsome Therapeutics, Inc.